Glycorex Transplantation AB Share Price

Equities

GTAB B

SE0000524530

Medical Equipment, Supplies & Distribution

End-of-day quote NORDIC GROWTH MARKET 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
0.912 SEK -14.77% Intraday chart for Glycorex Transplantation AB -0.87% -31.17%

Financials

Sales 2021 29.01M 2.65M 212M Sales 2022 37.39M 3.42M 274M Capitalization 303M 27.68M 2.22B
Net income 2021 -12M -1.1M -87.79M Net income 2022 -8M -731K -58.52M EV / Sales 2021 22.5 x
Net cash position 2021 33.08M 3.02M 242M Net cash position 2022 23.52M 2.15M 172M EV / Sales 2022 7.47 x
P/E ratio 2021
-56.1 x
P/E ratio 2022
-35.3 x
Employees 23
Yield 2021 *
-
Yield 2022
-
Free-Float 95.58%
More Fundamentals * Assessed data
Dynamic Chart
Glycorex Transplantation AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Glycorex Transplantation AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Glycorex Transplantation AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Glycorex Transplantation AB Announces Collaboration with University Hospital in Toulouse CI
Glycorex Transplantation AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Glycorex Transplantation AB and Cardiotec Vascularis Ltda. Sign Partnership Agreement CI
Glycorex Transplantation AB (Publ.) Announces Appointment of Erik Melgaard Pedersen as Head of Sales, Effective April 1, 2022 CI
Glycorex Transplantation AB Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Glycorex Transplantation AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 CI
Glycorex Transplantation Announces Agreement with Distributor in South Africa CI
More news
1 day-14.77%
1 week-0.87%
Current month+7.29%
1 month+4.35%
3 months-30.91%
6 months-22.71%
Current year-31.17%
More quotes
1 week
0.89
Extreme 0.89
1.07
1 month
0.76
Extreme 0.764
1.07
Current year
0.76
Extreme 0.764
1.44
1 year
0.76
Extreme 0.764
3.93
3 years
0.76
Extreme 0.764
13.02
5 years
0.76
Extreme 0.764
19.25
10 years
0.76
Extreme 0.764
19.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 31/12/21
Founder 71 31/12/95
Sales & Marketing - 31/03/22
Members of the board TitleAgeSince
Founder 71 31/12/95
Chairman 71 31/12/99
Director/Board Member 72 31/12/22
More insiders
Date Price Change Volume
26/04/24 0.912 -14.77% 21,435
25/04/24 1.07 0.00% 3,091
24/04/24 1.07 +6.47% 16,642
23/04/24 1.005 +12.92% 4,728
22/04/24 0.89 -3.26% 22,005

End-of-day quote NORDIC GROWTH MARKET, April 25, 2024

More quotes
Glycorex Transplantation publ AB is a Sweden-based medical device company engaged in the research, development, production and sales of medical devices within the field of organ transplantation. The Company's main product, Glycosorb-ABO, facilitates organ transplantation between different blood types. Additionally, the Company has developed complementary product variants, such as Glycosorb-ABO A/B-kolonn, designed for different patient categories, and Glycosorb-Xeno, which can facilitate transplants between animals and humans. As of December 31, 2011, Glycosorb-ABO was used in 103 transplantation centers in 22 countries. As of December 31, 2011, the Company had four wholly owned subsidiaries, namely Glycoprobe AB, Glycorex Transplantation, Glycorex UMC AB and Glycorex UBP AB.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. GTAB B Stock